| US 7,537,885 B2 | ||
| Composition for maintaining organ and cell viability | ||
| Joseph Fischer, Adelphia, N.J. (US); Jan Baker, Dixon, Calif. (US); and Robert G. L. Shorr, Edison, N.J. (US) | ||
| Assigned to Lifeblood Medical Inc., Adelphia, N.J. (US) | ||
| Filed on Mar. 22, 2007, as Appl. No. 11/689,876. | ||
| Application 11/689876 is a continuation of application No. 10/841756, filed on May 07, 2004, granted, now 7,220,538. | ||
| Prior Publication US 2007/0178435 A1, Aug. 02, 2007 | ||
| Int. Cl. A01N 1/00 (2006.01) | ||
| U.S. Cl. 435—1.1 [435/374; 435/383; 435/384; 435/405] | 23 Claims |
| 1. A method of preserving a mammalian heart, ex vivo, comprising contacting or perfusing a mammalian heart with an effective
amount of an aqueous composition that comprises:
a first phase comprising a base nutritive medium; and
a second phase comprising nanoparticles that comprise an outer lipophilic coating and an inner hydrophilic core, wherein
a) the first phase comprises physiologically compatible concentrations of water soluble or dispersible nutrients, and physiological
salts;
b) the nanoparticles of the second phase comprise lipids, fatty acids, sterols and free fatty acids; and
c) the two-phase composition has an osmolality of at least about 300 mOsM/kg, and wherein the nanoparticles have a mean diameter
ranging from about 100 nm to about 300 nm, and wherein the hydrophilic inner core of the nanoparticle contains a solution
or suspension comprising a moiety capable of binding and releasing oxygen, and the first phase comprises a composition of
the following table:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||